Streetbeat News

COEP

Coeptis Therapeutics Holdings Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Coeptis Therapeutics has received approval from the Nasdaq Hearings Panel to continue its listing on the Nasdaq exchange until January 15, 2025.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:24 am

Coeptis Therapeutics has completed its Phase 1 trial for COVID-19-related infections and is advancing its cell therapy platforms. The company raised $5.6 million in capital and is appealing a Nasdaq delisting decision. Strategic partnerships and new developments in cell therapy are key growth drivers.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:19 pm

Digital Turbine (APPS) shares surged over 20% in pre-market trading after reporting better-than-expected quarterly results. Other notable pre-market movers include Expion360 (XPON), Anew Medical (WENA), Luxurban Hotels (LUXH), Coeptis Therapeutics (COEP), Aspen Aerogels (ASPN), Sezzle (SEZL), Color Star Technology (ADD), Fluence Energy (FLNC), and Staffing 360 Solutions (STAF) among gainers. Losers include Cardlytics (CDLX), Outset Medical (OM), Bumble (BMBL), Viracta Therapeutics (VIRX), Greenlane Holdings (GNLN), JFrog (FROG), Know Labs (KNW), Dutch Bros (BROS), Fastly (FSLY), and Precigen (PGEN).

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 10:02 am

In Wednesday's pre-market session, several health care stocks experienced significant movements. Mustang Bio (MBIO) saw a 51.6% increase, while NeuroBo Pharmaceuticals (NRBO) rose by 30.78%. Rezolute (RZLT) and Akso Health Group (AHG) also saw gains of 25.0% and 16.26%, respectively. On the losing side, LifeStance Health Group (LFST) declined by 18.6%, and Lipella Pharmaceuticals (LIPO) fell by 11.84%.

Portfolio Pulse from Benzinga Insights

May 22, 2024 | 12:06 pm

Coeptis Therapeutics announced it will present its universal allogeneic SNAP-CAR NK cell therapy at the International Society for Cell & Gene Therapy (ISCT) 2024 conference, scheduled from May 28 to June 1.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 12:56 pm

In Thursday's after-market session, several healthcare stocks showed notable movements. Orgenesis, AN2 Therapeutics, GRI Bio, NuCana, Stoke Therapeutics, and Candel Therapeutics were among the gainers, with increases ranging from 4.99% to 8.5%. On the downside, Acorda Therapeutics, Aesthetic Medical Intl, Eiger BioPharmaceuticals, Coeptis Therapeutics, iSpecimen, and WAVE Life Sciences experienced declines between 4.96% and 8.9%. These movements reflect the dynamic nature of the healthcare sector in the stock market.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 8:31 pm

In Tuesday's after-market session, several healthcare stocks showed notable movements. Apollomics, Cara Therapeutics, Coeptis Therapeutics, Titan Pharma, BioSig Technologies, and Iridex were among the gainers, with increases ranging from 5.52% to 10.9%. On the downside, Akili, Mira Pharmaceuticals, Estrella Immunopharma, Virpax Pharmaceuticals, United Therapeutics, and ProSomnus experienced declines between 6.46% and 22.9%. Iridex and ProSomnus also released their Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 9:32 pm

In Thursday's after-market session, health care stocks saw significant movements. Geron (GERN) led the gainers with a 90.8% increase, while Kineta (KA) experienced the largest drop among the losers, declining by 8.3%. Notably, Akebia Therapeutics (AKBA) rose by 8.02% following its Q4 earnings report.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 9:33 pm

Coeptis Therapeutics has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications for its SNAP-CAR T and SNAP-CAR NK technology. This platform, which can target multiple antigens simultaneously, now extends its potential applications beyond oncology to various autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 2:02 pm

In Monday's after-market session, several healthcare stocks showed notable movements. BioSig Technologies, Coeptis Therapeutics, Alzamend Neuro, China Pharma Holding, AIM ImmunoTech, and Better Therapeutics were among the gainers, with increases ranging from 4.99% to 7.7%. On the downside, G1 Therapeutics, InVivo Therapeutics, 23andMe Holding, Calidi Biotherapeutics, Beyond Air, and Syra Health experienced declines between 6.61% and 37.5%. Notably, 23andMe's drop followed its Q3 earnings release three days prior, while Beyond Air's decline coincided with its Q3 earnings report.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.